Novel approaches in enhancing tumor radiosensitivity include inhibitors of distinct molecular pathways and key signalling factors such as Ras/Raf/MAPK, PI3K/Akt/mTOR (rapalogs, NVP-BEZ235, NVP-BGT226), c-Kit (imatinib, amuvatinib—also known as MP470), EGFR (cetuximab, erlotinib, sunitinib), PDGFR (sunitinib), and Hsp90 (NVP-AUY922). This evidence concerns the gene EGFR and neoplasm.